Martey Christine A, Vetrano Anna M, Whittemore Marilyn S, Mariano Thomas M, Heck Diane E, Laskin Debra L, Heindel Ned D, Laskin Jeffrey D
Department of Chemistry, Lehigh University, Bethlehem, PA 18015, USA.
Biochem Pharmacol. 2005 Dec 5;70(12):1726-34. doi: 10.1016/j.bcp.2005.10.001. Epub 2005 Nov 2.
Psoralens and ultraviolet light A (PUVA) are used in the treatment of a variety of epidermal proliferative and inflammatory disorders. These compounds are known to intercalate and photo crosslink DNA. Specific receptor proteins for psoralens have also been identified. We describe a novel activity of a thiol reactive derivative, iodomercurio-4',5'-dihydrotrimethylpsoralen (iodomercurio-H2TMP) in keratinocytes. Without UVA, this psoralen was found to be an effective inhibitor of interferon-gamma (IFN-gamma)-signaling as measured by induction of nitric oxide biosynthesis (IC50 = 0.8 microM). This activity was increased (IC50 = 0.1 microM) when the cells were depleted of intracellular glutathione (GSH) with buthionine sulfoximine. In keratinocytes, IFN-gamma stimulates expression of inducible nitric oxide synthase (NOS2). Although iodomercurio-H2TMP did not alter NOS2 enzymatic activity, it blocked IFN-gamma-induced expression of NOS2 mRNA and protein, an effect that was enhanced in GSH-depleted cells. Iodomercurio-H2TMP was found to readily inhibit IFN-gamma signaling in transient transfection assays using NOS2 promoter/luciferase reporter constructs. NOS2 gene expression is known to require a variety of transcription factors including STAT-1, NF-kappaB and AP-1. Using mobility shift assays the psoralen, at concentrations that inhibit nitric oxide biosynthesis, had no effect on the DNA binding activity of STAT-1 or NF-kappaB. However, iodomercurio-H2TMP was found to suppress AP-1. These data indicate that iodomercurio-H2TMP acts at sulfhydryl-sensitive sites to inhibit NOS2. Moreover, this is dependent on early events in the IFN-gamma signal transduction pathway. Inhibition of AP-1 suggests that the psoralen functions by interfering with an important transcription factor that regulates expression of NOS2 in keratinocytes.
补骨脂素和紫外线A(PUVA)用于治疗多种表皮增殖性和炎症性疾病。已知这些化合物可嵌入并光交联DNA。补骨脂素的特异性受体蛋白也已被鉴定出来。我们描述了一种硫醇反应性衍生物碘汞基-4',5'-二氢三甲基补骨脂素(碘汞基-H2TMP)在角质形成细胞中的新活性。在没有紫外线A的情况下,发现这种补骨脂素是干扰素-γ(IFN-γ)信号传导的有效抑制剂,通过一氧化氮生物合成的诱导来衡量(IC50 = 0.8微摩尔)。当用丁硫氨酸亚砜胺使细胞内谷胱甘肽(GSH)耗尽时,这种活性增强(IC50 = 0.1微摩尔)。在角质形成细胞中,IFN-γ刺激诱导型一氧化氮合酶(NOS2)的表达。虽然碘汞基-H2TMP没有改变NOS2的酶活性,但它阻断了IFN-γ诱导的NOS2 mRNA和蛋白质的表达,在GSH耗尽的细胞中这种作用增强。在使用NOS2启动子/荧光素酶报告构建体的瞬时转染实验中,发现碘汞基-H2TMP很容易抑制IFN-γ信号传导。已知NOS2基因表达需要多种转录因子,包括STAT-1、NF-κB和AP-1。使用迁移率变动分析,在抑制一氧化氮生物合成的浓度下,补骨脂素对STAT-1或NF-κB的DNA结合活性没有影响。然而,发现碘汞基-H2TMP可抑制AP-1。这些数据表明碘汞基-H2TMP作用于巯基敏感位点以抑制NOS2。此外,这取决于IFN-γ信号转导途径中的早期事件。对AP-1的抑制表明补骨脂素通过干扰调节角质形成细胞中NOS2表达的重要转录因子发挥作用。